A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three-Way Crossover, Pharmacokinetic and Pharmacodynamic Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS).

Trial Profile

A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three-Way Crossover, Pharmacokinetic and Pharmacodynamic Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS).

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2012

At a glance

  • Drugs Tirasemtiv (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 10 Dec 2012 Results were presented at the 23rd International Symposium on ALS/MND, according to a Cytokinetics media release.
    • 01 Sep 2012 Tolerability and pharmacodynamic results published in the Amyotrophic Lateral Sclerosis.
    • 15 Apr 2011 Results presented at the 63rd Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top